Abnormal HDL lipid and protein composition following pediatric cancer treatment: an associative study

Lipids in Health and Disease

Research

Isabelle Bouchard¹  Caroline Meloche¹  Mélanie Napartuk²  Valérie Marcil²  Sophia Morel²  Véronique Bélanger²  Caroline Laverdière³  Daniel Sinnett³  Serge Sultan⁴  Daniel Curnier⁵ 

[1] Research Centre, CHU Sainte-Justine, 3175 Chem. de la Côte-Sainte-Catherine, H3T 1C5, Montreal, QC, Canada;Research Centre, CHU Sainte-Justine, 3175 Chem. de la Côte-Sainte-Catherine, H3T 1C5, Montreal, QC, Canada;Department of Nutrition, Université de Montréal, Montreal, QC, Canada;Research Centre, CHU Sainte-Justine, 3175 Chem. de la Côte-Sainte-Catherine, H3T 1C5, Montreal, QC, Canada;Department of Pediatrics, Université de Montréal, Montreal, QC, Canada;Research Centre, CHU Sainte-Justine, 3175 Chem. de la Côte-Sainte-Catherine, H3T 1C5, Montreal, QC, Canada;Department of Psychology, Université de Montréal, Montreal, QC, Canada;Research Centre, CHU Sainte-Justine, 3175 Chem. de la Côte-Sainte-Catherine, H3T 1C5, Montreal, QC, Canada;School of Kinesiology and Physical Activity Sciences, Université de Montréal, Montreal, QC, Canada;

关键词: Dyslipidemias;    Lipoproteins;    Apolipoproteins;    High density lipoprotein;    Cholesterol;    Children;    Adolescents;    Chemotherapeutic agents;    Clinical studies;    Obesity;   

DOI  :  10.1186/s12944-023-01822-2

 received in 2023-02-20, accepted in 2023-04-24,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundLong-term childhood cancer survivors (CCS) are at high risk of having dyslipidemia including low high density lipoprotein cholesterol (HDL-C). However, little is known about the prevalence of low HDL-C and the impact of therapy exposure on HDL composition early after treatment is terminated.MethodsThis associative study included 50 children and adolescents who had completed their cancer treatments (< 4 years). Clinical characteristics (demographic, diagnosis, treatment, anthropometric parameters), fasting plasma lipids, apoliporoteins (Apo) A-I and composition of HDL fractions (HDL2 and HDL3) were assessed. Data were stratified according to the presence of dyslipidemia and median doses of therapeutic agents and compared using Fisher exact or Mann–Whitney tests. Univariate binary logistic regression analyses were carried out to evaluate the associations between the clinical and biochemical characteristics and having low HDL-C. Composition of HDL2 and HDL3 particles was assessed in a sub-group of 15 patients and compared to 15 age- and sex-matched healthy controls using Wilcoxon paired test.ResultsOf the 50 pediatric cancer patients included in this study (mean age: 11.30 ± 0.72 y; mean time since end of treatment: 1.47 ± 0.12 y; male: 38%), 8 had low HDL-C (16%), all of which were adolescent at diagnosis. Higher doses of doxorubicin were associated with lower HDL-C and Apo A-I levels. In hypertriglyceridemic patients and compared to normolipidemics, triglycerides (TG) content was greater in HDL2 and HDL3 fractions whereas esterified cholesterol (EC) content was lower in HDL2. Enrich TG content of HDL3 and lower EC of HDL2 was found in patients exposed to ≥ 90 mg/m2 doxorubicin. Factors positively associated with the risk of having low HDL-C were age, being overweight or obese and exposure to doxorubicin ≥ 90 mg/m2. Compared to healthy controls, a sub-group of 15 patients showed higher TG and free cholesterol (FC) content of HDL2 and HDL3 and lower EC content in HDL3.ConclusionsOverall, we found abnormalities in HDL-C and Apo A-I levels and in HDL composition early after pediatric cancer treatment that are influenced by age, overweight or obesity status and exposure to doxorubicin.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 6

Fig. 1

Fig. 22

Fig. 2